Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biogen Idec
(NQ:
BIIB
)
228.33
+3.31 (+1.47%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
...
14
15
16
17
18
19
20
21
22
...
38
39
Next >
Biogen Soars On Upgrade; Why Lilly, Roche Won't Block Its Alzheimer's Opportunity
October 13, 2022
Even a percentage of the Alzheimer's market could mean $7 billion for Biogen.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
October 13, 2022
Upgrades
Via
Benzinga
Is This Stock a Buy After Soaring by 37%?
October 06, 2022
Don't press the buy button too fast.
Via
The Motley Fool
Elliott Wave Technical Analysis: Biogen, Inc. - Thursday, Oct. 13
October 13, 2022
Biogen Inc. is moving as predicted, looking for this pullback to this support as we have had a huge gap to the upside.
Via
Talk Markets
Is Seagen Stock a Buy Now?
October 12, 2022
It's growing faster than competitors, but headwinds might soon bog it down.
Via
The Motley Fool
Roche's Muscular Atrophy Treatment Improves Motor Function In Pretreated Patients
October 12, 2022
Via
Benzinga
Does Biogen's Recent Win Make It a Must-Buy Stock?
October 12, 2022
Will Biogen investors be let down again, or is this the real deal?
Via
The Motley Fool
4 Biotech Stocks With Huge Incoming Catalysts
October 12, 2022
All four of these drugmakers are expecting important FDA approval decisions over the next few months.
Via
The Motley Fool
Biotech Stocks Well-Positioned For The Fourth Quarter
October 12, 2022
The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far.
Via
Talk Markets
Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers
October 10, 2022
Via
Benzinga
These 7 Biotech Stocks Are Set to Boom in 2023
October 10, 2022
This article looks at seven biotech stocks that look like good options to move significantly higher in 2023
Via
InvestorPlace
Eli Lilly Leads 5 Stocks To Watch In Bear Market
October 08, 2022
Eli Lilly is holding up, while others crumbled Friday amid the market sell-off.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2022
October 07, 2022
Upgrades
Via
Benzinga
One Of Eli Lilly's Most Anticipated Drugs Could Hit The Market Next Year
October 06, 2022
The Street is closely watching Lilly's efforts in obesity and Alzheimer's.
Via
Investor's Business Daily
Should You Sell Your FANGMAN Stocks?
October 05, 2022
In addition to energy, investors have been fleeing to healthcare stocks for safety. And they have been selling the big tech names, especially the semiconductors.
Via
Talk Markets
Hey Biogen Investors, Don’t Chase BIIB Stock!
October 05, 2022
If BIIB stock already reflects Biogen's early-stage Alzheimer's disease study results, then the next move could easily be to the downside.
Via
InvestorPlace
Will Investors Notice Exciting Sign On Biogen's Chart?
October 05, 2022
If history is any guide, there may be good fortune ahead for shares of Biogen (NASDAQ:BIIB). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the...
Via
Benzinga
2 Signals to Watch Before Buying SAVA Stock
October 05, 2022
SAVA stock got ahead of itself in September, but if it continues to pull back, a solid entry point could emerge for this risky biotech play.
Via
InvestorPlace
Peering Into Biogen's Recent Short Interest
October 04, 2022
Biogen's (NASDAQ:BIIB) short percent of float has risen 9.52% since its last report. The company recently reported that it has 2.07 million shares sold short, which is 1.61% of all regular shares that...
Via
Benzinga
Vyant Bio Inc. (NASDAQ: VYNT): Leading a New Biotech Move to Combat Diseases Affecting the Nervous System
October 04, 2022
Biotechnology companies such as Biogen Inc. (NASDAQ: BIIB), Alector Inc.
Via
Benzinga
Large Cap Biopharmaceuticals: Core Holdings For Your Portfolio
October 03, 2022
Now that some clarity is apparent for drug pricing legislation you should have a few large-cap biopharmaceutical stocks in your portfolio.
Via
Talk Markets
US Supreme Court Turns Away Biogen's Last Effort To Reinstate Tecfidera Patent
October 03, 2022
The U.S. Supreme Court decided not to hear the case related to reinstating the patent of Biogen Inc's (NASDAQ: BIIB) blockbuster drug Tecfidera.
Via
Benzinga
Stock Market Falls, S&P 500 Hits Bear Lows; Biogen, Nike, Micron Are Key Movers: Weekly Review
September 30, 2022
The major indexes fell, with the S&P 500 breaking below bear market lows.
Via
Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
September 29, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
September 29, 2022
Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial...
Via
Benzinga
Netflix, Biogen And Other Big Gainers From Wednesday
September 29, 2022
U.S. stocks closed higher with the Dow Jones surging more than 500 points on Wednesday. Here is the list of some big stocks recording gains in the previous session.
Via
Benzinga
7 Growth Stocks to Buy to Tap Into a Hidden Bull Market
September 28, 2022
It's become a bit easier for investors to find growth stocks to buy hidden amid the bear market.
Via
InvestorPlace
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
September 28, 2022
Via
Benzinga
Here's How Much $100 Invested In Biogen 20 Years Ago Would Be Worth Today
September 28, 2022
Biogen (NASDAQ:BIIB) has outperformed the market over the past 20 years by 2.9% on an annualized basis producing an average annual return of 10.93%. Currently, Biogen has a market capitalization of...
Via
Benzinga
Alphabet To $136? Plus This Analyst Slashes PT On United Natural Foods
September 28, 2022
Truist Securities cut the price target on Alphabet Inc. (NASDAQ: GOOGL) from $145 to $136. Truist Securities analyst Youssef Squali maintained a Buy rating on the stock. Alphabet shares rose 2.5% to...
Via
Benzinga
< Previous
1
2
...
14
15
16
17
18
19
20
21
22
...
38
39
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.